Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers.
作者信息
Liang Lilian Yan, Wong Vincent Wai-Sun, Wong Grace Lai-Hung, Yip Terry Cheuk-Fung
机构信息
Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.
State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
出版信息
Clin Mol Hepatol. 2023 Jan;29(1):113-117. doi: 10.3350/cmh.2022.0333. Epub 2022 Oct 31.
Abstract
摘要
相似文献
1
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers.迈向乙型肝炎病毒功能性治愈——血清病毒标志物治疗期动力学的影响
Clin Mol Hepatol. 2023 Jan;29(1):113-117. doi: 10.3350/cmh.2022.0333. Epub 2022 Oct 31.
2
Quantitative Hepatitis B Surface Antigen, the Trustworthy Biomarker for Functional Cure of Chronic Hepatitis B.定量乙型肝炎表面抗原，慢性乙型肝炎功能性治愈的可靠生物标志物。
Gut Liver. 2023 Mar 15;17(2):179-180. doi: 10.5009/gnl230070.
3
Targeting liver metabolism: a pathway to cure hepatitis B virus?靶向肝脏代谢：治愈乙型肝炎病毒的途径？
Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(7):645-647. doi: 10.1080/17474124.2023.2226390. Epub 2023 Jun 18.
4
Genomics on the road to functional cure of hepatitis B.乙肝功能性治愈之路上的基因组学
J Hepatol. 2024 Jan;80(1):6-7. doi: 10.1016/j.jhep.2023.11.002. Epub 2023 Nov 18.
5
Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?为什么接受抗病毒治疗的慢性乙型肝炎幼儿的功能性治愈率相当高？
Hepatol Int. 2024 Feb;18(1):296-298. doi: 10.1007/s12072-023-10597-8. Epub 2023 Oct 31.
6
Use of serum Golgi protein 73 for screening chronic hepatitis B virus infection patients needing antiviral therapy in the community.血清高尔基体蛋白73在社区筛查需要抗病毒治疗的慢性乙型肝炎病毒感染患者中的应用。
Chin Med J (Engl). 2022 Nov 20;135(22):2741-2743. doi: 10.1097/CM9.0000000000002051.
7
[Imperatives to strengthen HBsAg screening and expand antiviral therapy indications on hepatitis B among the general population].[加强一般人群乙肝表面抗原筛查及扩大乙肝抗病毒治疗指征的必要性]
Zhonghua Gan Zang Bing Za Zhi. 2023 Jun 20;31(6):646-648. doi: 10.3760/cma.j.cn501113-20220521-00271.
8
Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring.利用乙型肝炎核心相关抗原检测优化治疗后监测。
Clin Mol Hepatol. 2024 Apr;30(2):293-296. doi: 10.3350/cmh.2024.0101. Epub 2024 Feb 19.
9
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.实现慢性乙型肝炎的完全治愈：乙型肝炎病毒的新治疗靶点。
Clin Mol Hepatol. 2022 Jan;28(1):17-30. doi: 10.3350/cmh.2021.0093. Epub 2021 Jul 20.
10
Antiviral therapy, HBsAg seroclearance and late recurrence of hepatitis B-related hepatocellular carcinoma.抗病毒治疗、乙肝表面抗原血清清除及乙肝相关肝细胞癌的晚期复发
J Hepatol. 2022 Nov;77(5):1471-1472. doi: 10.1016/j.jhep.2022.07.005. Epub 2022 Jul 19.
引用本文的文献
1
Correspondence on Editorial regarding "HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB".关于社论“慢性乙型肝炎患者长期使用核苷（酸）类似物治疗时，第4周乙肝病毒前基因组RNA和乙肝核心相关抗原水平降低预示乙肝表面抗原反应良好”的通信
Clin Mol Hepatol. 2023 Jan;29(1):191-193. doi: 10.3350/cmh.2022.0410. Epub 2022 Nov 22.
本文引用的文献
1
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?如何实现乙肝功能性治愈：停止核苷（酸）类似物，加用干扰素或开发新药？
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.
2
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.核苷（酸）类似物停药后HBsAg消失的概率取决于HBV基因型和病毒抗原水平。
J Hepatol. 2022 May;76(5):1042-1050. doi: 10.1016/j.jhep.2022.01.007. Epub 2022 Jan 29.
3
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus.实现慢性乙型肝炎的完全治愈：乙型肝炎病毒的新治疗靶点。
Clin Mol Hepatol. 2022 Jan;28(1):17-30. doi: 10.3350/cmh.2021.0093. Epub 2021 Jul 20.
4
Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.乙型肝炎核心相关抗原反映慢性乙型肝炎患者的病毒复制和蛋白产生。
Chin Med J (Engl). 2021 Mar 17;134(10):1160-1167. doi: 10.1097/CM9.0000000000001418.
5
Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.三个臭皮匠，顶个诸葛亮：乙肝核心相关抗原作为新的乙型肝炎病毒相关肝细胞癌预测因子。
Clin Mol Hepatol. 2021 Oct;27(4):524-534. doi: 10.3350/cmh.2021.0012. Epub 2021 Feb 23.
6
Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.血清乙型肝炎核心相关抗原可预测乙型肝炎 e 抗原阴性患者的肝细胞癌。
J Gastroenterol. 2020 Sep;55(9):899-908. doi: 10.1007/s00535-020-01700-z. Epub 2020 Jun 17.
7
Novel biomarkers for the management of chronic hepatitis B.用于慢性乙型肝炎管理的新型生物标志物。
Clin Mol Hepatol. 2020 Jul;26(3):261-279. doi: 10.3350/cmh.2020.0032. Epub 2020 Jun 15.
8
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.慢性乙型肝炎临床试验设计和终点的指导原则——2019 年 EASL-AASLD HBV 治疗终点会议报告。
J Hepatol. 2020 Mar;72(3):539-557. doi: 10.1016/j.jhep.2019.11.003. Epub 2019 Nov 12.
9
Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.前基因组 HBV RNA 和乙型肝炎核心相关抗原可预测乙型肝炎 e 抗原阴性慢性乙型肝炎患者核苷（酸）类似物治疗抑制后的结局。
Hepatology. 2020 Jul;72(1):42-57. doi: 10.1002/hep.31026.
10
How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved?我们如何确定是否实现了对HBV感染的功能性治愈？
Clin Gastroenterol Hepatol. 2020 Mar;18(3):548-550. doi: 10.1016/j.cgh.2019.08.033. Epub 2019 Aug 22.
Zotero 插件